The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study
Maria D’Souza(Gentofte Hospital), Morten Schou(Copenhagen University Hospital), Charlotte Andersson(Herlev Hospital), Lars Køber(University of Copenhagen), Gunnar Gislason(Copenhagen University Hospital), Inge Marie Svane(Copenhagen University Hospital), Emil Loldrup Fosbøl(University of Copenhagen), Kasper Iversen(University of Copenhagen), Christian Torp‐Pedersen(University of Copenhagen), Dorte Nielsen(Herlev Hospital), Peter Rasmussen(University of Copenhagen), Christian Madelaire(Odense University Hospital), Finn Gustafsson(University of Copenhagen)
Cited by 166
Related Papers
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012
|European Journal of Heart Failure|2012|2.6k
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
|New England Journal of Medicine|2003|2.5k